References of "Brown, JP"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detail10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Bone, H.G.; Wagman, R.B.; Brandi, M.L. et al

in Lancet Diabetes & Endocrinology (2017), 5

Detailed reference viewed: 40 (2 ULiège)
Full Text
Peer Reviewed
See detailTen years of Denosumab (DMAB) treatment in postmenopausal women with osteoporosis. Results from the FREEDOM Extension trial.
Bone, H.G.; Brandi, M.L.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(Supplement 1), 135-136

Detailed reference viewed: 217 (1 ULiège)
Full Text
Peer Reviewed
See detailrelationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment
Ferrari, S.; ADAMI, S.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(Supplement 1), 49-50

Detailed reference viewed: 44 (0 ULiège)
Full Text
Peer Reviewed
See detailA randomized double-blind study of Denosumab (DMAB) compared with Zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates
Miller, P.; Pannacciulli, N.; Brown, J.P. et al

in Osteoporosis International (2016, April), 27(SUPPLEMENT1), 42

Detailed reference viewed: 74 (1 ULiège)
Full Text
Peer Reviewed
See detailA randomized double-blind study of denosumab compared with zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonate.
MILLER, P.D.; PANNACCIULLI, N.; BROWN, J.P. et al

in Arthritis and Rheumatology (2016), 67(S10), 1181-1182

Detailed reference viewed: 55 (2 ULiège)
Full Text
Peer Reviewed
See detailCan we use bone turnover markers as targets for antiresorptive treatment in postmenopausal osteoporosis ? an analysis from two phase 3 clinical trials.
BROWN, J.P.; DAKIN, P.; HADJI, P. et al

in Arthritis and Rheumatology (2015), 67(S10), 515-517

Detailed reference viewed: 26 (0 ULiège)
Full Text
Peer Reviewed
See detailRelationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment
FERRARI, S.; LIBANATI, C.; LIN, CJF. et al

in Arthritis and Rheumatology (2015), 67(s10), 487-489

Detailed reference viewed: 30 (0 ULiège)
Full Text
Peer Reviewed
See detailPercentage of women achieving non-osteoporotic BMD T-scores at the lumbar spine (LS) and total hip (TH) during up to 8 years of Denosumab (Dmab) treatment
Ferrari, S; Libanati, C; Lin, CJF et al

in Osteoporosis International (2015), 26(S1), 149-150

Detailed reference viewed: 56 (1 ULiège)
Full Text
Peer Reviewed
See detailPercentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment
Ferrari, S; Libanati, C; Lin, CJF et al

in Arthritis and Rheumatism (2014), 66(11), 986-987

Detailed reference viewed: 47 (1 ULiège)
Full Text
Peer Reviewed
See detailStrontium ranelate improves osteoarthritis symptoms compared to placebo in patients with knee OA: The SEKOIA study
Bruyère, Olivier ULiege; Richette, P; Bellamy, N et al

in Osteoporosis International (2013, April), 24(Suppl.1), 49-51

Detailed reference viewed: 45 (2 ULiège)
Full Text
Peer Reviewed
See detailInhibition de la sclérostine par le romosozumab chez des femmes ménopausées ayant une DMO basse : résultats de l'étude de phase 2
Brown, JP; McClung, MR; Grauer, A et al

in Revue du Rhumatisme (2013), 80(S1), 73

Detailed reference viewed: 27 (1 ULiège)
Full Text
Peer Reviewed
See detailInhibition of sclerostin with romosozumab in postmenopausal women with low BMD : phase 2 trial results
McClung, M; Grauer, A; Boonen, S et al

in Osteoporosis International (2013), 24(1), 38-39

Detailed reference viewed: 145 (2 ULiège)
Full Text
Peer Reviewed
See detailDenosumab treatment of postmenopausal women with osteoporosis for 6 years : results from the first 3 years of the freedom extension
Papapoulos, S; Brown, JP; Chapurlat, R et al

in Osteoporosis International (2012, March), 23(S2), 76

Detailed reference viewed: 97 (1 ULiège)
Full Text
Peer Reviewed
See detailTreatment of postmenopausal women with osteoporosis for six years with denosumab : three-year results from the freedom extension
Chapurlat, R; Papapoulos, S; Brown, JP et al

in Annals of the Rheumatic Diseases (2012), 71(3), 588

Detailed reference viewed: 53 (1 ULiège)
Full Text
Peer Reviewed
See detailDenosumab therapy in postmenopausal women with osteoporosis : results from the first two years of the freedom trial extension
Bone, H. G.; Chapurlat, R.; Brandi, M. L. et al

in Endocrine Reviews (2011), 32

Detailed reference viewed: 46 (1 ULiège)
Full Text
Peer Reviewed
See detailSafety observations from denosumab long-term extension and cross-over studies in postmenopausal women with osteoporosis
Bone, H. G.; Chapurlat, R.; Libanati, C. et al

in Journal of Bone and Mineral Research (2011), 26(S1), 22-23

Detailed reference viewed: 78 (1 ULiège)
Full Text
Peer Reviewed
See detailExtended safety observations from denosumab administration in postmenopausal women from FREEDOM and FREEDOM extension trials
Brown, J. P.; Bone, H. G.; Chapurlat, R. et al

in Arthritis and Rheumatism (2011), 63(S10), 431-432

Detailed reference viewed: 22 (3 ULiège)
Full Text
Peer Reviewed
See detailRisedronate, a highly effective, short-term oral treatment for Paget’s disease: a dose-response study
Brown, JP; Hosking, DJ; Ste-Marie, LG et al

in Calcified Tissue International (1999), 64

Detailed reference viewed: 7 (0 ULiège)